English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background   Assessing the pre- and post-test probability of disease in the context of routine health care is challenging. We wished to study how test performance parameters relating to clinical utility vary by clinical indication in a ‘real-world’ setting.Methods   The diagnostic accuracy of serum total B 12  and Active-B 12 ® (holotranscobalamin) was evaluated in a primary care population, using serum methylmalonic acid as the reference standard. We used electronic requesting to establish the clinical indication for each request. Routine requests from primary care for serum total B 12  were included if creatinine was also measured and estimated glomerular filtration rate was at least 60 mL/min/1.73 m 2 .Results   Clinical indications included peripheral neuropathy ( n = 168), anaemia ( n = 168), cognitive decline ( n = 125), suspected dietary deficiency ( n = 76), other ( n = 362). For peripheral neuropathy, the area under the receiver operator curve ± 95% confidence interval (AUC ± CI) was 0.63 (0.54–0.71) ( P = 0.002) for total B 12  and 0.68 (0.60–0.77) ( P &lt; 0.0001) for Active-B 12 ®. For anaemia, AUC ± CI was 0.56 (0.47–0.66) ( P = 0.10) for total B 12  and 0.69 (0.59–0.78) ( P &lt; 0.0001) for Active-B 12 ®. For cognitive decline, AUC ± CI was 0.54 (0.43–0.65) ( P = 0.26) for total B 12  and 0.69 (0.58–0.80) ( P = 0.0002) for Active-B 12 ®. The pre–post-test change in probability of disease varied by clinical indication.Conclusion   Combining diagnostic accuracy studies and electronic testing in a ‘real-world’ setting allows clinical utility to be assessed by clinical indication. Wider application of this would permit more personalised laboratory medicine. In this study, diagnostic performance of total B 12  and Active-B 12 ® varied across all indications. Active-B 12 ® provided better discrimination, but this may have reflected the cut-offs used.

annals of clinical biochemistry

Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B12 and Active-B12® (holotranscobalamin) in the diagnosis of vitamin B12 deficiency